KALA BIO, Inc.

KALASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1479419

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	—	—	—	—	—
Research and Development Expense	—	—	—	—	$27.3M
Selling, General and Administrative Expense	—	$65.0M	$105.1M	$81.1M	$65.0M
Operating Expenses	$39.7M	$85.6M	$141.5M	$102.6M	$25.4M
Operating Income (Loss)	-$39.7M	-$81.7M	-$130.2M	-$96.2M	-$88.2M
Interest Expense	—	$7.3M	$8.4M	$8.6M	$8.5M
Nonoperating Income (Expense)	-$2.5M	$36.9M	-$12.4M	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$55.9M	$86.8M	$139.4M	$221.6M	$154.3M
Assets, Current	$52.9M	$85.9M	$124.4M	$171.4M	$105.5M
Cash and Cash Equivalents, at Carrying Value	$50.9M	$70.5M	$92.1M	$77.3M	$85.4M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$15.3M	$9.6M	$11.6M
Inventory, Net	—	—	$8.6M	$5.2M	$4.6M
Liabilities	$48.4M	$67.8M	$122.6M	$121.6M	$124.6M
Liabilities, Current	$8.3M	$25.7M	$37.4M	$22.2M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$27.9M	-$78.9M	-$108.2M	-$90.7M	-$92.7M
Net Cash Provided by (Used in) Investing Activities	-$429.0K	$62.7M	$70.8M	-$78.2M	-$1.3M
Net Cash Provided by (Used in) Financing Activities	$8.5M	-$7.9M	$42.6M	$160.6M	$9.0M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)